Jim Cramer Says Buy Celgene on Weakness Over Revlimid
<I>TheStreet's</I> Jim Cramer says Celgene, which ended Friday's session down more than 4%, is a great buy because the drug maker is led by a great CEO.
TheStreet's Jim Cramer says Celgene (CELG), which ended Friday's session down more than 4-percent, is a great buy because the drugmaker is led by a great CEO. Cramer says Celgene CEO Robert Hugin has done a great job of diversifying the company's drug portfolio. Shares of Celgene ended lower on word the UK would not immediately approve Celgene's cancer drug, Revlemed, for reimbursement. Cramer believes the drug will eventually be approved for reimbursement everywhere.
At the time of publication, Cramer was long ___.
